Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barnaby Pickering

Senior Writer

London, UK

Barnaby lives and works in Yorkshire. Having graduated from University College London with a master's degree in biomedical engineering in 2020, Barnaby is passionate about cutting-edge medical technology. Key areas of focus for Barnaby include diabetes, nanotechnology, machine learning and artificial intelligence.

Latest From Barnaby Pickering

Minute Insight: Cordis-MedAlliance Deal Formalized, Less Than One Year After Announcement

The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.

Minute Insights Cardiovascular

Holocare Hopes To Bring New Dimensions To Surgical Planning

The company has developed a method to convert DICOM images into 3D holograms that can be projected onto VR headsets. Medtech Insight caught up with CEO Alison Sundset to find out how Holocare is paving the way for a more integrated, collaborative form of pre-surgical planning.

Robotic Surgery Platform Technologies

Minute Insight: SpectralMD Signs Another Contract With BARDA, Worth $149m

The diagnostic company has secured more government funding for DeepView, a product it has developed to assess the healing of certain types of wound. In total, BARDA has supported SpectralMD with almost a quarter of a billion dollars.

Diagnostic Imaging Wound Management

Minute Insight: Vicarious’ Future Gets Precarious

The surgical robotics start-up may be de-listed from the New York Stock Exchange (NYSE) due to its low current share price. Some analysts believe the company can survive long enough to earn FDA de novo clearance for its robotic surgical system.

Commercial Financing

Oxford Biodynamics Releases EpiSwitch Prostate Cancer Test Early

The UK-based company is hoping to quickly take market share with its blood-based diagnostic that uses epigenetic data to assist cancer diagnosis.

Launches Cancer

Minute Insight: Virtual Incision Draws In Another $30m With Its Table-Top Surgical Robot

The cash will be used to extend the company’s development runway “well into 2025.”  

Robotic Surgery Innovation
See All
UsernamePublicRestriction

Register